Optieum Biotechnologies Inc. is a pre-clinical stage biotechnology company developing innovative scFv antibody-based therapies for the treatment of patients with cancers.
Our platform technology, Eumbody System, enables Optieum to develop and detect scFv-based product candidates that specifically bind, modulate, and ultimately optimize the immune-cell function for oncology targets.
L17 is a novel anti-CD19 T-cell based scFv with enhanced anti-tumor cytotoxicity, higher proliferation capacity.gy targets.
Our platform technology, Eumbody System, enables Optieum to develop and detect scFv-based product candidates that specifically bind, modulate, and ultimately optimize the immune-cell function for oncology targets.
L17 is a novel anti-CD19 T-cell based scFv with enhanced anti-tumor cytotoxicity, higher proliferation capacity.gy targets.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Japan
Year Founded:
2020
Main Therapeutic Focus:
Oncology
Lead Product in Development:
Anti-CD19 CAR-T cell
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
BIO DOUBLE HELIX SPONSORS
BIO HELIX SPONSORS
